Gilead’s Veklury (remdesivir) Receives the TGA’s Approval to Treat Adults and Adolescents with Severe COVID-19 Symptoms
MHLW Expedites the Reviews of Gilead’s Remdesivir to Treat Patients with COVID-19 in Japan
Shots:
- The TGA authorization follows the recent data shared by EMA and Singapore Health Sciences Authority for remdesivir’s approval in EU, Singapore and, Japan for COVID-19 patients
- TGA’s approval was made within 2 weeks of the receipt of the submission while the provisional approval is based on preliminary data valid for 6 years. Additionally, the company plans filling full registration confirming the safety and efficacy of the drug to the TGA committee
- Remdesivir is an investigational drug targeted reduce hospitalization time for COVID-19 while the drug will be available for severely unwell, requiring oxygen or high-level support to breathe, and in-hospital care
Click here to read full press release/ article | Ref: Therapeutic Goods Administration | Image: Behance